Commonwealth Equity Services’s Takeda Pharmaceutical TAK Stock Holding History

Commonwealth Equity Services’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$362K	Buy	22,598 +2,564	+13%	+$42.4K	﹤0.01%	3601
2026 Q1	$371K	Buy	20,034 +735	+4%	+$12.9K	﹤0.01%	3482
2025 Q4	$301K	Sell	19,299 -1,443	-7%	-$20.6K	﹤0.01%	3651
2025 Q3	$304K	Buy	20,742 +1,060	+5%	+$15.7K	﹤0.01%	3631
2025 Q2	$304K	Sell	19,682 -1,948	-9%	-$28.8K	﹤0.01%	3564
2025 Q1	$322K	Buy	21,630 +3,916	+22%	+$54.9K	﹤0.01%	3433
2024 Q4	$235K	Sell	17,714 -2,389	-12%	-$32.8K	﹤0.01%	3627
2024 Q3	$286K	Sell	20,103 -3,765	-16%	-$53.4K	﹤0.01%	3393
2024 Q2	$309K	Sell	23,868 -1,827	-7%	-$24.2K	﹤0.01%	3262
2024 Q1	$357K	Sell	25,695 -3,053	-11%	-$44.4K	﹤0.01%	3112
2023 Q4	$410K	Buy	28,748 +1,152	+4%	+$16.3K	﹤0.01%	2897
2023 Q3	$427K	Sell	27,596 -2,760	-9%	-$42.7K	﹤0.01%	2723
2023 Q2	$477K	Sell	30,356 -4,220	-12%	-$69.1K	﹤0.01%	2665
2023 Q1	$569K	Sell	34,576 -530	-2%	-$8.44K	﹤0.01%	2444
2022 Q4	$547K	Sell	35,106 -30,751	-47%	-$430K	﹤0.01%	2398
2022 Q3	$854K	Sell	65,857 -2,133	-3%	-$29.7K	﹤0.01%	2011
2022 Q2	$954K	Sell	67,990 -8,081	-11%	-$115K	﹤0.01%	1938
2022 Q1	$1.09M	Sell	76,071 -3,103	-4%	-$45.6K	﹤0.01%	1926
2021 Q4	$1.08M	Sell	79,174 -41,893	-35%	-$588K	﹤0.01%	1932
2021 Q3	$1.98M	Sell	121,067 -49,029	-29%	-$823K	0.01%	1429
2021 Q2	$2.86M	Buy	170,096 +31,289	+23%	+$533K	0.01%	1189
2021 Q1	$2.53M	Buy	138,807 +41,674	+43%	+$750K	0.01%	1167
2020 Q4	$1.77M	Buy	97,133 +70,039	+259%	+$1.23M	0.01%	1293
2020 Q3	$483K	Sell	27,094 -3,152	-10%	-$57.4K	﹤0.01%	1987
2020 Q2	$542K	Sell	30,246 -1,490	-5%	-$26.7K	﹤0.01%	1822
2020 Q1	$481K	Sell	31,736 -3,959	-11%	-$71.8K	﹤0.01%	1722
2019 Q4	$704K	Buy	35,695 +1,767	+5%	+$33.8K	﹤0.01%	1651
2019 Q3	$583K	Buy	33,928 +8,328	+33%	+$144K	﹤0.01%	1719
2019 Q2	$453K	Sell	25,600 -9,967	-28%	-$181K	﹤0.01%	1879
2019 Q1	$724K	Buy	+35,567	New	+$716K	﹤0.01%	1507

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Commonwealth Equity Services's TAK Position: Q2 2026 in Review

Commonwealth Equity Services increased its Takeda Pharmaceutical (TAK) stake by 13% in Q2 2026, buying an estimated $42.4K and bringing the position to 22,598 shares worth $362K. The position accounts for ﹤0.01% of the portfolio, ranked #3601.

Commonwealth Equity Services first reported a position in TAK in Q1 2019 and has held it in 30 quarters since. The position peaked at $2.86M in Q2 2021. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Commonwealth Equity Services held 22,598 shares of Takeda Pharmaceutical worth $362K as of Q2 2026.
Commonwealth Equity Services bought 2,564 Takeda Pharmaceutical shares in Q2 2026, an estimated $42.4K.
Takeda Pharmaceutical made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #3601 holding.
Commonwealth Equity Services first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 30 quarters since.
Commonwealth Equity Services's Takeda Pharmaceutical position peaked at $2.86M in Q2 2021.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.